Q-omics provides the consensus-scored FOXRED1 profile across patient tissues and cancer cell-line models. FOXRED1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FOXRED1 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, FOXRED1 protein abundance shows 20,148 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, BLCA, and LUAD as cancer lineages where FOXRED1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXRED1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXRED1 survival associations across molecular data types. FOXRED1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXRED1 RNA expression–survival associations across cancer types. High FOXRED1 expression shows unfavorable associations in UVM, ACC and BLCA, but favorable associations in KIRP, UCEC and READ. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FOXRED1 RNA expression.
This table summarizes FOXRED1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FOXRED1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXRED1 shows higher tumor expression in BLCA, STAD, LUAD, HNSC, LUSC and COAD. The BLCA box plot shows higher FOXRED1 RNA expression in tumor versus normal tissue (log2 FC = +0.620, t-test p < 0.001).
This table shows molecular features associated with FOXRED1 in patient tissues and cancer cell lines. In patient samples, FOXRED1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXRED1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
